Kornimate/medical-research-clean huggingface dataset:
this study explores how short-term immersive vr with exercises and ergonomic training can reduce neck pain, improve movement, strength, and work productivity in computer users who are at high risk due to prolonged screen time and poor posture.

Conditions: Neck Pain; Neck Disability; Neck Endurance; Work Productivity; Cervical Range of Motion

Summary: the goal of this clinical trial is to learn if a short-term immersive virtual reality (vr) intervention, combined with exercises and ergonomic training, can help treat neck pain in computer users. it will also explore how safe and effective this approach is. the main questions it aims to answer are: does immersive vr with exercise and ergonomic training reduce neck pain and disability? does it improve cervical range of motion, neck muscle endurance, and work productivity? researchers will compare the effects before and after the intervention to see how well it works for managing neck pain in computer users. participants will: use immersive vr exercises and receive ergonomic training over a short period attend assessment sessions to measure pain, movement, endurance, and work productivity follow specific guidelines for posture and workplace adjustments during the study


Eligibility criteria:
inclusion criteria: 1. computer users of age 18 to 50 years old with history of more than 6 hours of screen time. (9) 2. complaints of neck pain. exclusion criteria: 1. individuals having complains of vertigo 2. radiating pain 3. balance issues 4. motion sickness 5. recent cervical fractures/dislocations or whiplash injuries 6. complaints of photosensitivity 7. complaints of frequent headaches

Keywords: ergonomic training neck pain cervical rom neck endurance neck disability work productivity computer users
combination trial of patupilone and carboplatin in adult patients with advanced solid tumors

Conditions: Advanced Solid Tumors

Summary: this study will evaluate the maximum tolerated dose (mtd) and dose-limiting toxicity (dlt) of patupilone combined with carboplatin in adult patients with advanced solid tumors who progressed despite standard therapy or for whom no standard therapy exists or who might benefit from treatment with carboplatin


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed advanced solid tumors who have progressed despite standard therapy, or for whom no standard therapy exists, or who might benefit from treatment with carboplatin * a minimum of 4 weeks since the last treatment with chemotherapy * who performance status 0 (able to carry out all normal activity without restriction) or 1 (restricted in physically strenuous activity but ambulatory and able to carry out work) * age ≥ 18 * adequate hematological parameters * no major impairment of renal or hepatic function * written informed consent obtained exclusion criteria: * major surgery less than 4 weeks prior to study entry and/or not fully recovered from surgery * chemotherapy or investigational compound less than 4 weeks prior to study entry, or planned while participating in the study * prior administration of an epothilone * hypersensitivity to carboplatin. patients resistant to carboplatin are not recommended to enter the trial * radiotherapy (rt) less than 4 weeks prior to study entry (except for palliative therapy of distant metastases), or planned rt while participating in the study * diarrhea within 7 days prior to start of treatment. unresolved bowel obstruction * peripheral neuropathy \> grade 1 (mild) * symptomatic brain metastases * colostomy other protocol-defined inclusion/exclusion criteria may apply

Keywords: cancer maximum tolerated dose dose-limiting toxicity patupilone carboplatin pharmacokinetics
brain stimulation for neurological patients

Conditions: Alzheimer Disease

Summary: this is a prospective double-blind randomized placebo-controlled crossover clinical trial


Eligibility criteria:
inclusion criteria: * clinically stable patients with probable alzheimer's disease (diagnosis according to icd-10 criteria (f00)) * at least 3 months of stable antidementive therapy or no antidementive therapy necessary * signed written informed consent * monthly pregnancy test for women in childbearing years * age \>= 18 years exclusion criteria: * non-compliance with the protocol * pregnant or breastfeeding women * relevant intracerebral pathology unrelated to the alzheimers's disease (e.g. brain tumor) * hemophilia or other blood clotting disorders * cortisone treatment within the last 6 weeks before first treatment * thrombosis
cd34+ selected stem cell for poor graft function or graft failure

Conditions: Graft Failure; Poor Graft Function

Summary: the proposed trial is a single arm, non-randomized, single center pilot study utilizing clinimacs cd34 reagent system for patients following allogeneic hematopoietic stem cell transplant (hsct) requiring treatment of graft dysfunction or failure.

the primary objective of the study is to estimate the incidence of engraftment with sustained recovery of blood counts, including, absolute neutrophil cell (anc) and platelet engraftment. * anc engraftment is defined as anc of ≥ 0.5 × 10\^9/l for three consecutive laboratory values obtained on different days. date of anc recovery is the date of the first of three consecutive laboratory values where the anc is ≥ 0.5 × 10\^9/l. * platelet engraftment should reflect no platelet transfusions administered for seven consecutive days. report the date of the first of three consecutive laboratory values ≥ 20 × 10\^9/l obtained on different days. the secondary objective of the study is to estimate the incidence of graft-versus-host disease (gvhd) and side effects that can be attributed to the clinimacs cd34 selected cellular product.

Eligibility criteria:
inclusion criteria: * recipient of allogeneic transplantation, adult ≥18 years, from any type of donor including matched related, matched unrelated, mismatched related or mismatched unrelated or haploidentical donor transplant. * documented evidence of graft dysfunction or failure (a-c): 1. primary graft failure: graft failure is defined as failure to achieve neutrophil engraftment by day +28 or lack of donor chimerism \> 50% by day 45 not due to the underlying malignancy; 2. poor graft function is defined by at least 2 of the following 3 criteria: hemoglobin \< 8 g/dl, anc \< 0.5x109/l, and platelets \< 20x109/l. the cytopenia must be unexplained (such as by disease relapse) and unresponsive to hematopoietic growth factors and must last at least 4 weeks; 3. secondary graft failure is defined as poor graft function associated with donor chimerism \< 5% after initial engraftment * transplanted donor availability * negative pregnancy test within seven (7) days of product infusion for women of childbearing potential. exclusion criteria: * graft failure due to disease relapse or evidence of disease relapse or progression * donor unavailable or unable to collect peripheral hpc by apheresis * responsive to conventional measures (such as, hematopoietic growth factor) * allergic reaction to murine proteins or iron dextran * women of childbearing potential with positive serum hcg
acute kidney injury in patients on dapagliflozin and other antidiabetic medications

Conditions: Acute Kidney Injury

Summary: to compare, by insulin use at the index date, the incidence of hospitalization for acute kidney injury (aki) among patients with type 2 diabetes mellitus who are new users of dapagliflozin with those who are new users of antidiabetic drugs (ads) in classes other than sodium-glucose cotransporter 2 (sglt2) inhibitors, insulin monotherapy, metformin monotherapy, or sulfonylurea monotherapy

the overall goal of this research study is to estimate the risk of hospitalization for acute kidney injury in patients who are prescribed dapagliflozin compared to patients prescribed other specific oral antidiabetic drugs. dapagliflozin and other antidiabetic drugs are used to treat type 2 diabetes mellitus. because of the mechanism of action for dapagliflozin and results from small safety monitoring studies, there is interest in further evaluating the safety of dapagliflozin in large populations. the study will be implemented in three administrative health care data sources in two countries: in the united kingdom, the clinical practice research datalink (cprd); and in the united states, the centers for medicare and medicaid services (cms) medicare databases and the healthcore integrated research database (hirdsm). individuals in the databases will be included in the study if they meet the following age criteria; 18 years and older (cprd and hird), or 65 years or older (medicare); and if they did not have type 1 diabetes, are new users of one of the study drugs and meet the criteria of at least 180 days of electronic data before their first prescription of the study drug. the study period starts july 1, 2013 in cprd, january 1, 2014 in pharmo and january 9, 2014 in the united states data sources, and will end at the latest available data at each database at the time of analysis.

Eligibility criteria:
inclusion criteria: 1. receive newly prescribed dapagliflozin (with or without other ads) or receive a newly prescribed ad (with or without other ads) in a class other than sglt2 inhibitors, insulin monotherapy, metformin monotherapy, or sulfonylurea monotherapy; 2. do not have any diagnostic code indicating type1 diabetes; 3. are aged 18 years or older at the index date for cprd patients, 18-64 years for hirdsm patients, or 65 years or older for medicarepatients; and 4. have been enrolled in the data source for at least 180 days before the first prescription or dispensing dapagliflozin or eligible index comparator ad exclusion criteria: -previous diagnosis of chronic kidney failure
intranasal civamide for episodic cluster headache

Conditions: Episodic Cluster Headache

Summary: this is a 49-day study to evaluate the effectiveness of intranasal civamide (zucapsaicin) in the treatment of an episodic cluster headache period compared to placebo (medically inactive substance which does not contain any active ingredients).


Eligibility criteria:
* at least 2 year history of episodic cluster headache (meeting ihs criteria) * at least 2 previous episodes * expected duration of cluster period is at least 6 weeks but not longer than 24 weeks * at least 1 but not more than 8 headaches on each of the 3 days immediately prior to treatment

Keywords: headache cluster ec episodic cluster
non-invasive monitoring of pediatric kidney transplant recipients and immunosuppression personalization: an open-labeled multicenter randomized controlled study

Conditions: Pediatric Kidney Disease; Transplant;Failure,Kidney

Summary: currently, the monitoring of children receiving a kidney transplantation includes surveillance biopsies to detect subclinical rejection and signs of toxicity of immunosuppressive drugs (tacrolimus). the hypothesis of the study is that the combination of non-invasive biomarkers (donor-derived cell-free dna and virus-specific t cells) will allow both the safe discontinuation of surveillance biopsies and the personalization of the exposure to calcineurin inhibitors among pediatric kidney transplant recipients.

monitor is an open label multicenter prospective randomized trial of superiority with two active comparators (4 parallel groups 1:1:1:1). arm a: monitoring by dd-cfdna; arm b: monitoring by t-vis; arm c: monitoring by dd-cfdna+ t-vis; comparator arm: current standard of care based on surveillance biopsies and biological monitoring main objectives and primary endpoints : 1. to demonstrate that the use of an integrative score of allograft rejection including dd-cfdna measurement allows the reduction of the number of surveillance biopsies. endpoint: number of biopsy performed in each arm 2. to demonstrate that steering immunosuppression based on tvis numbers allows the reduction of the exposition to calcineurin inhibitors. endpoint: tacrolimus exposure assessed as the mean of the residual concentration of tacrolimus between m6 and m24

Eligibility criteria:
inclusion criteria: * age less than 21 years old at transplantation * single renal transplant from a deceased or a living donor. * absence of pregnancy confirmed by a negative pregnancy test in women in child-bearing period. * subject and legal guardians are willing and able to provide signed written informed consent and to comply with the study procedures * patients affiliated to health insurance system including aide médicale de l'etat (ame) exclusion criteria: * history of multi-organ transplant (interference with rejection natural history) * no surveillance biopsy planned * adult patient (or legal guardians) with limited understanding of the french language preventing him from receiving informed information on the protocol

Keywords: kidney transplant pediatric rejection
avanafil versus sildenafil in spinal cord injury erectile dysfunction

Conditions: Erectile Dysfunction

Summary: the main goal of this study is to compare the use of avanafil versus sildenafil in spinal cord injury erectile dysfunction. the study has the characteristics of a non- inferiority, randomized, crossover, open clinical trial. the principal variable is the iief-ef (erectile function domain questionnaire of the international index of erectile function iief). this is an interventional study


Eligibility criteria:
inclusion criteria: * spinal cord injury * erectile dysfunction * no medical contraindication to use avanafil and/or sildenafil * able to provide informed consent * able to complete questionnaires exclusion criteria: * medical contraindication to use avanafil and/or sildenafil * no spinal cord injury * congenital spinal cord injury * not able to provide informed consent * not able to complete questionnaires
screening for sleep disordered breathing with minimally obtrusive sensors

Conditions: Sleep Apnea Syndromes; Snoring

Summary: the purpose of this study is to learn more about breathing disorders during sleep. the investigators want to learn how breathing sounds made during sleep relate to breathing disorders during sleep.

the purpose of this study is to evaluate the feasibility of assessing breathing problems during sleep with minimally obtrusive sensors (a bedside microphone and wireless pulse oximeter worn on the fingertip). the investigators will use the data collected with these sensors to develop algorithms for automatically detecting sleep apnea events. subjects will be asked to place unobtrusive sensors (bedside microphone and wireless pulse oximeter) in their home sleep environment. the subjects will start the at-home data collection before they fall asleep, and stop the data collection the next morning when they wake. the subjects will then return the sensors to the investigator for analysis. we are looking for people interested in participating in the at-home portion of our study. we will only collect at-home data for one night of sleep per subject. after this one night, no further data collection or monitoring will occur. subjects will be compensated for their time. a standard sleep-breathing questionnaire (the "berlin questionnaire") will be administered. this questionnaire is widely used as a screening tool to determine if a person may have disordered breathing during sleep. this questionnaire consists of 10 multiple-choice questions related to snoring, daytime sleepiness, and other related conditions.

Eligibility criteria:
inclusion criteria: * age 21-89 * no self-reported sleep breathing problems exclusion criteria: * prior diagnosis for a sleep breathing problem (such as sleep apnea) * self-reported insomnia * history of stroke * nasal or soft palate surgery in the last 12 months * use of a breathing assistance device (such as a cpap machine)

Keywords: sleep apnea snoring
efficacy and safety of rituximab to that of calcineurin inhibitors in children with steroid dependent nephrotic syndrome

Conditions: Nephrotic Syndrome

Summary: nephrotic syndrome in children is primarily caused by minimal change disease. majority of these patients respond well to corticosteroids. however, as many as 70% of children with nephrotic syndrome experience at least one relapse, and 30% develop a more complicated course with frequent relapses (frns)(≥2 relapses/ 6 months) with or without steroid dependency (sdns)(relapse during tapering or within 2 weeks after discontinuation of corticosteroids). repeated and prolonged courses of steroids in these children often result in long-term complications. the goal of the treatment is to reduce the rate of relapses, the cumulative dose of corticosteroids, and the incidence of serious complications. in order to minimize the side effects of steroid therapy, different steroid sparing agents such as cyclophosphamide, calcineurin inhibitors(cni), levamisole, and mycophenolate mofetil (mmf) have been used in sdns. whereas cni are usually considered the steroid sparing drug class of first choice, rituximab is increasingly used as alternative to minimize cni toxicity. various prospective studies suggest that rituximab, a b cell depleting monoclonal antibody, could be a safe and effective alternative to steroid or immunosuppressants to achieve and maintain remission in this population.single rituximab course have been shown to be efficacious for 6 to 12 months and the side effect profile observed to date is very benign. studies comparing the usefulness of these agents are lacking. in our proposed randomized controlled trial, the investigators want to compare the efficacy and safety of cni to that of rituximab in treating children with sdns.


Eligibility criteria:
inclusion criteria: * children between 3 and 16 years with sdns * minimal change disease/fsgs/mespgn/ as per kidney biopsy report. * estimated glomerular filtration rate (egfr) \>80 ml/min per 1.73 m2 at study entry. * remission at study entry (trace or nil proteinuria, as determined by the dipstick test or \<100 mg/dl for at least 3 days). * not received any steroid sparing agent previously. * parents willing to give informed written consent. * ability to swallow tablet exclusion criteria: * known etiology (e.g., lupus erythematosus, iga nephropathy, amyloidosis, malignancy, other secondary forms of ns) * patients with severe leucopenia (leucocytes \ 50 iu/l ) at enrolment. * known active chronic infection (tuberculosis, hiv, hepatitis b or c) live vaccination within 1 mo
electro-neuro-muscular stimulation in icu

Conditions: Myopathy; Neuropathy

Summary: we will examine whether the application of electro-neuro-muscular stimulation (enms) in critical care patients, can decrease the impact or severity of the critical illness myopathy (cim) or neuropathy. we will also assess whether electro-neuro-muscular stimulation affect the incidence density rate of nosocomial pneumonia in the icu. patients will be divided into two groups, group a and group b chosen at random. in group a conventional physiotherapy will be applied while in group b, enms will also be applied additional to physiotherapy, in the quadriceps muscles. the total time of applying enms will be 1 hour, it will be applied before the start of the physiotherapy per day of hospitalization and for 10 days in each patient. the definition of cim will be based on pathology muscular biopsy (quadriceps). patients will undergo biopsy on the 1st and 11th day after entering the study. the technique of gomori trichrome will be used to determine the existence or absence of myopathy. in addition the atpase technique will be applied at different prices of ph (ph: 9,4, ph: 4,6 and ph : 4.3), thus achieving a separation of myopathy and neuropathy. the primary outcome of the study will be the incidence of myopathy in both groups, at day 12th. considering that the incidence of myopathy in critically ill patients is 80% reducing this rate by 50% in the intervention group using statistical power equal to 0.80 up to a level of p \<0.05, 12 number of patients will be required in each group.


Eligibility criteria:
inclusion criteria: patients aged\>18 years old and \<85 years old, hospitalized in the icu for at least 96 hours exclusion criteria: pregnancy, autoimmune disease, pre-existing known neuromuscular diseases, presence of bone fractures on the lower extremities, use of corticoids

Keywords: icu, myopathy, neuropathy, pneumonia
optimization of the diagnosis of bone fractures in patients treated in the emergency department by using artificial intelligence for reading radiological images in comparison with traditional reading by the emergency doctor.

Conditions: Artificial Intelligence; Bone Fracture

Summary: as part of the management of a patient with suspected bone fractures, emergency physicians are required to make treatment decisions before obtaining the imaging reading report from the radiologist, who is generally not available only a few hours after the patient's admission, or even the following day. this situation of the emergency doctor, alone interpreting the radiological image, in a context of limited time due to the large flow of patients to be treated, leads to a significant risk of interpretation error. unrecognized fractures represent one of the main causes of diagnostic errors in emergency departments. this comparative study consists of two cohorts of patients referred to the emergency department for suspected bone fracture. the first will be of interest to patients whose radiological images will be interpreted by the reading of the emergency doctor systematically doubled by the reading of the artificial intelligence. the other will interest a group of patients cared for by the simple reading of the emergency doctor. all of the images from both groups of patients will be re-read by the establishment's group of radiologists no later than 24 hours following the patient's treatment. a centralized review will be provided by two expert radiologists. also, patients in both groups will be systematically recalled in the event of detection of an unknown fracture for hospitalization.


Eligibility criteria:
inclusion criteria: * major subject * patient admitted to the emergency department for suspected peripheral fractures in the extremities of the upper limb and/or lower limb (wrist/hand and ankle/foot). * patient affiliated to or entitled to a social security system * patient having received written and informed information about the study and having signed a free and informed consent to participate in the study. exclusion criteria: * patient previously admitted to the emergency room for suspicion of fractures and not included in the study * patient admitted to the emergency room with suspicion of multiple fractures * refusal to participate in the study * protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision and under judicial protection * pregnant, breastfeeding or parturient patient
automated telephone follow-up in the swedish prison and probation services

Conditions: Affect; Alcohol Consumption; Substance Abuse

Summary: the purpose of this study is to investigate whether automated telephony may be used for daily assessments of paroled offenders, and whether a brief intervention based on these daily assessments may result in a more positive development compared to daily assessments only.

to study whether automated telephony could be used in paroled offenders to perform daily assessment of variables associated with recidivism in crime and to study the effects of a brief intervention based on these assessments during 30 days following probation.

Eligibility criteria:
inclusion criteria: * convicted criminals subject to parole * access to a mobile telephone * assigned parole officer at parole exclusion criteria: * no knowledge of spoken swedish * additional intervention such as intensive supervision with electronic monitoring, or in-patient care at a health and rehabilitation clinic

Keywords: paroled offenders interactive voice response stress mental symptoms alcohol consumption substance use